These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Risk of Endophthalmitis Based on Cumulative Number of Anti-VEGF Intravitreal Injections. Israilevich RN; Mansour H; Patel SN; Garg SJ; Klufas MA; Yonekawa Y; Regillo CD; Hsu J Ophthalmology; 2024 Jun; 131(6):667-673. PubMed ID: 38182029 [TBL] [Abstract][Full Text] [Related]
27. Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome. Dossarps D; Bron AM; Koehrer P; Aho-Glélé LS; Creuzot-Garcher C; Am J Ophthalmol; 2015 Jul; 160(1):17-25.e1. PubMed ID: 25892127 [TBL] [Abstract][Full Text] [Related]
28. LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study. Freiberg FJ; Brynskov T; Munk MR; Sørensen TL; Wolf S; Wirth MA; Becker M; Michels S Retina; 2017 Dec; 37(12):2341-2346. PubMed ID: 28099318 [TBL] [Abstract][Full Text] [Related]
29. Incidence of endophthalmitis following intravitreal anti VEGF injections at a tertiary care hospital in Pakistan. Shaheen F; Awan MA; Hafeez A; Haq A; Malik RZ J Pak Med Assoc; 2021 Apr; 71(4):1184-1188. PubMed ID: 34125768 [TBL] [Abstract][Full Text] [Related]
30. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA; Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087 [TBL] [Abstract][Full Text] [Related]
31. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Xu Y; Tan CS Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451 [TBL] [Abstract][Full Text] [Related]
32. Association of compounded bevacizumab with postinjection endophthalmitis. VanderBeek BL; Bonaffini SG; Ma L JAMA Ophthalmol; 2015 Oct; 133(10):1159-64. PubMed ID: 26270251 [TBL] [Abstract][Full Text] [Related]
33. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates. Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167 [TBL] [Abstract][Full Text] [Related]
35. The Pandemic Is Not Associated with Endophthalmitis Decrease after Anti-Vascular Endothelial Growth Factor Injections. Lum F; Li S; Liu L; Li C; Parke DW; Williams GA Ophthalmology; 2022 Jun; 129(6):719-721. PubMed ID: 35041903 [No Abstract] [Full Text] [Related]
36. The Influence of Universal Face Mask Use on Endophthalmitis Risk after Intravitreal Anti-Vascular Endothelial Growth Factor Injections. ; Patel SN; Tang PH; Storey PP; Wolfe JD; Fein J; Shah SP; Chen E; Abbey A; Ferrone PJ; Shah CP; Liang MC; Stem MS; Ali Khan M; Yonekawa Y; Garg SJ Ophthalmology; 2021 Nov; 128(11):1620-1626. PubMed ID: 34019955 [TBL] [Abstract][Full Text] [Related]
37. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S Retina; 2008; 28(10):1395-9. PubMed ID: 18827737 [TBL] [Abstract][Full Text] [Related]
39. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. McCannel CA Retina; 2011 Apr; 31(4):654-61. PubMed ID: 21330939 [TBL] [Abstract][Full Text] [Related]
40. Incidence of endophthalmitis after intravitreal application of anti VEGF therapy at the University Clinical Center in Tuzla, Bosnia and Herzegovina. Terzić S; Pilavdžić A; Nadarević Vodenčarević A Med Glas (Zenica); 2015 Aug; 12(2):202-5. PubMed ID: 26276660 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]